Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect

Leukemia Research

Volumn 34, Issue 12, 2010, Pages 1670-1673

  Sarro, Shannon M ^a   Unruh, Tammy L ^a   Zuccolo, Jonathan ^a   Sanyal, Ratna ^a   Luider, Joanne M ^b   Auer Grzesiak, Iwona A ^a,b   Mansoor, Adnan ^a,b   Deans, Julie P ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b FOOTHILLS HOSPITAL   (Canada)

Author keywords

CD20 mRNA; CD20 protein; Chronic lymphocytic leukemia; Quantitation

Indexed keywords

CD20 ANTIGEN; MESSENGER RNA;

ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; GENE EXPRESSION; GENETIC DISORDER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ANTIGENS, CD20; B-LYMPHOCYTES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION, GENETIC;

EID: 78149359058     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.06.031     Document Type: Article

References (11)

1. Almasri N.M., Duque R.E., Iturraspe J., Everett E., Braylan R.C. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992, 40:259-263.
2. D'Arena G., Musto P., Cascavilla N., Dell'Olio M., Di Renzo N., Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000, 64:275-281.
3. Ginaldi L., De Martinis M., Matutes E., Farahat N., Morilla R., Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998, 51:364-369.
4. Golay J., Lazzari M., Facchinetti V., Bernasconi S., Borleri G., Barbui T., et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001, 98:3383-3389.
5. Polyak M.J., Deans J.P. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002, 99:3256-3262.
6. Zuccolo J., Unruh T.L., Deans J.P. Efficient isolation of highly purified tonsil B lymphocytes using RosetteSep with allogeneic human red blood cells. BMC Immunol 2009, 10:30.
7. Petrie R.J., Deans J.P. Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J Immunol 2002, 169:2886-2891.
8. Mankai A., Bordron A., Renaudineau Y., Martins-Carvalho C., Takahashi S., Ghedira I., et al. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells. Cancer Res 2008, 68:7512-7519.
9. Henry C., Deschamps M., Rohrlich P.S., Pallandre J.R., Remy-Martin J.P., Callanan M., et al. Identification of an alternative CD20 transcript variant in B cell malignancies coding for a novel protein associated to rituximab resistance. Blood 2010, 115:2420-2429.
10. Caligaris-Cappio F., Ghia P. The normal counterpart to the chronic lymphocytic leukemia B cell. Best Pract Res Clin Haematol 2007, 20:385-397.
11. Inamdar K.V., Bueso-Ramos C.E. Pathology of chronic lymphocytic leukemia: an update. Ann Diagn Pathol 2007, 11:363-389.